All In Biotech

Drug Trial Radar · NCT00468923

Heart Outcomes Prevention Evaluation-3

Last checked: Nov 20, 2026Latest source record: Oct 25, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 12,705 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

12,705

Actual

Start

May 2007

Primary completion

Dec 2015

Study completion Jan 2016

Sponsor

Lead sponsor
Population Health Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 3, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Factorial
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Heart disease and stroke are major causes of death and disability worldwide and are largely preventable. Cholesterol and blood pressure are major cardiovascular risk factors. Previous studies have shown that certain drugs can effectively and safely lower cholesterol and blood pressure and prevent heart attacks and strokes. Such studies have been conducted primarily in people who had already sustained a heart attack or a stroke, or in people with high cholesterol and blood pressure levels. However, most heart attacks and strokes occur in people with average ("normal") cholesterol and blood pressure. Therefore, in the HOPE-3 trial the investigators will evaluate whether a cholesterol lowering drug, rosuvastatin, and a combination blood pressure lowering pill, candesartan/hydrochlorothiazide, used alone or together can reduce the risk of heart attacks, stroke and their sequelae in people without known heart disease and at average risk.

Conditions

  • Cardiovascular Disease
  • Stroke

Interventions

  • Candesartan/HCTDrug

    Candesartan 16 mg/HCT 12.5 once daily

  • RosuvastatinDrug

    Rosuvastatin 10 mg once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The composite of; Cardiovascular death, non-fatal myocardial infarction, non-fatal stroke.Time frame: Biannually
  2. The composite of; cardiovascular death, resuscitated cardiac arrest, non-fatal myocardial infarction, non-fatal stroke, heart failure, arterial revascularizationsTime frame: Biannually

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Hamilton General Hospital

    Hamilton, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.